The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics
Open Access
- 10 June 2008
- journal article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 9 (1), 1-9
- https://doi.org/10.1186/1745-6215-9-35
Abstract
During the last decades, many basic and clinical research have pointed to the role of B vitamins (folate, vitamins B6 and B12) and n-3 fatty acids as nutritional factors that might have a protective effect on the development of cardiovascular diseases (CVD). The SU.FOL.OM3 (SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids) trial is a randomized double-blind, placebo-controlled, secondary-prevention trial designed to test the efficacy of 5-methyl tetra-hydro-folates (5-MTHF) supplementation, in combination with vitamin B6 and B12 and/or n-3 fatty acids, at nutritional doses, on fatal and non fatal ischemic CVD in a 2 × 2 factorial design. A total of 2501 patients aged between 45 and 80 years who had a past history, in the previous year, of myocardial infarction (n = 1151) or instable angina pectoris (n = 711) or an ischemic stroke (n = 639) were included. Subjects have to be supplemented and followed up for five years. Daily supplementation comprised nutritional doses of 5-MTHF (560 μg), vitamin B6 (3 mg) and B12 (20 μg) and/or n-3 fatty acids (600 mg with an EPA:DHA ratio of 2:1). A factorial design 2 × 2 has been applied to investigate the separate effects of the B-vitamins, and the n-3 fatty acids, as well as their interaction as compared to the placebo. The primary endpoint is a combination of myocardial infarction, ischemic stroke and cardiovascular death. Secondary endpoints are events of the composite endpoint taken separately, total mortality, and other cardiovascular events such as acute coronary syndromes, coronary revascularization, cardiac failure, arrhythmia... Baseline socio-demographic and medical characteristics of participants are totally comparable in the four randomized groups. Current Controlled Trials ISRCTN41926726Keywords
This publication has 38 references indexed in Scilit:
- Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trialsAmerican Heart Journal, 2006
- Intake of Fish and n3 Fatty Acids and Risk of Coronary Heart Disease Among JapaneseCirculation, 2006
- n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillatorsEP Europace, 2005
- Fish Oil Supplementation and Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients With Implantable DefibrillatorsJAMA, 2005
- Accumulated Evidence on Fish Consumption and Coronary Heart Disease MortalityCirculation, 2004
- Lack of benefit of dietary advice to men with angina: results of a controlled trialEuropean Journal of Clinical Nutrition, 2003
- Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular DiseaseCirculation, 2002
- Dietary Intake of Folate and Risk of Stroke in US Men and WomenStroke, 2002
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991
- The Inverse Relation between Fish Consumption and 20-Year Mortality from Coronary Heart DiseaseNew England Journal of Medicine, 1985